Relay Therapeutics Inc ((RLAY)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Relay Therapeutics Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor.’ The study aims to evaluate the efficacy and safety of RLY-2608 in combination with fulvestrant compared to capivasertib with fulvestrant in treating HR+/HER2- breast cancer with PIK3CA mutation.
The study tests two drug combinations: RLY-2608 + fulvestrant and capivasertib + fulvestrant. RLY-2608 is administered orally, while fulvestrant is given intramuscularly, targeting advanced breast cancer treatment.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment efficacy. Patients are allocated to either the experimental or active comparator group to assess outcomes.
The study is currently recruiting, with an estimated start date of July 31, 2025. The primary completion and estimated study completion dates are yet to be announced. The last update was submitted on July 29, 2025.
Relay Therapeutics’ study could significantly influence its stock performance by demonstrating effective treatment options, potentially increasing investor confidence. The study’s outcome may also impact the competitive landscape in the breast cancer treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.